Loading organizations...
§ Private Profile · Nantes, Pays de la Loire, France
Clinical-stage biotech develops small molecule therapeutics for neurodegenerative and orphan diseases, focused on modulating the ISR.
InFlectis BioScience is a clinical-stage biotech based in Nantes, France, developing small molecule therapeutics that target misfolded proteins in neurodegenerative and orphan diseases. The company focuses on modulating the Integrated Stress Response (ISR) to address conditions such as amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT), with its lead candidate IFB-088 designed as an orally available therapy. It has raised $8.76 million across two funding rounds from investors including GO CAPITAL, Remiges Ventures, and Crédit Mutuel Equity. Recent developments include securing exclusive patent rights from the University of Chicago for IFB-088 and IFB-048 in June 2021, and expanding its leadership team with appointments like Chairman Mark Pykett. InFlectis BioScience was founded in 2013 by Philippe GuEdat and Pierre Miniou.
InFlectis BioScience has raised $6.8M across 1 funding round.
InFlectis BioScience has raised $6.8M in total across 1 funding round.
InFlectis BioScience has raised $6.8M in total across 1 funding round.
InFlectis BioScience's investors include Credit Mutuel Innovation, Remiges Ventures, Go Capital, Participations Besancon.
InFlectis BioScience has raised $6.8M across 1 funding round. Most recently, it raised $6.8M Series A in June 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 3, 2016 | $6.8M Series A | Credit Mutuel Innovation, Remiges Ventures | GO Capital, Participations Besancon | Announced |